Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM and 7 more

Show all authors

Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM

International journal of radiation oncology, biology, physics12 Feb 2017Cited by 108 (Europe PMC)

PMID28463149PMCIDPMC5603177DOI10.1016/j.ijrobp.2017.02.004PepBankPUB-28463149

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with locally advanced prostate cancer, extended goserelin improved disease-free survival versus short-term ADT, reducing failure by 29% (P<.0001).
In plain wordsIn men with prostate cancer, extended goserelin improved disease-free survival compared with short-term treatment.
Peptide
Goserelin
Outcome
IncreaseDisease-free survival
Study
n = 1,520
Comparator
Short-term ADT plus radiotherapy
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg per month · Additional 24 monthsAs given in this study (human).
Measurements
Relative reduction in failure rate
29%
LTAD versus STAD; adjusted analysis; P<.0001
Source sentences
Summary
In analysis adjusted for prognostic covariates, LTAD improved disease-free survival (29% relative reduction in failure rate, P<.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin).
Report a problemFND-2846314901
02HumanRandomized controlled trialEfficacy outcome
In men with locally advanced prostate cancer, extended goserelin reduced local progression by 46% versus short-term ADT (P=.02).
In plain wordsIn men with prostate cancer, extended goserelin reduced local progression compared with short-term treatment.
Peptide
Goserelin
Outcome
DecreaseLocal progression
Study
n = 1,520
Comparator
Short-term ADT plus radiotherapy
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg per month · Additional 24 monthsAs given in this study (human).
Measurements
Relative reduction in local progression
46%
LTAD versus STAD; adjusted analysis; P=.02
Source sentences
Summary
local progression (46% relative reduction, P=.02)
1 context sentence(design, population, supporting numbers)
Summary · context
to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin).
Report a problemFND-2846314902
03HumanRandomized controlled trialEfficacy outcome
In men with locally advanced prostate cancer, extended goserelin reduced distant metastases by 36% versus short-term ADT (P<.0001).
In plain wordsIn men with prostate cancer, extended goserelin reduced distant metastases compared with short-term treatment.
Peptide
Goserelin
Outcome
DecreaseDistant metastases
Study
n = 1,520
Comparator
Short-term ADT plus radiotherapy
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg per month · Additional 24 monthsAs given in this study (human).
Measurements
Relative reduction in distant metastases
36%
LTAD versus STAD; adjusted analysis; P<.0001
Source sentences
Summary
distant metastases (36% relative reduction, P<.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin).
Report a problemFND-2846314903
04HumanRandomized controlled trialEfficacy outcome
In men with locally advanced prostate cancer, extended goserelin improved disease-specific survival versus short-term ADT, with 30% relative reduction (P=.003).
In plain wordsIn men with prostate cancer, extended goserelin improved disease-specific survival compared with short-term treatment.
Peptide
Goserelin
Outcome
IncreaseDisease-specific survival
Study
n = 1,520
Comparator
Short-term ADT plus radiotherapy
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg per month · Additional 24 monthsAs given in this study (human).
Measurements
Relative reduction (disease-specific survival)
30%
LTAD versus STAD; adjusted analysis; P=.003
Source sentences
Summary
disease-specific survival (30% relative reduction, P=.003)
1 context sentence(design, population, supporting numbers)
Summary · context
to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin).
Report a problemFND-2846314904
05HumanRandomized controlled trialEfficacy outcome
In men with locally advanced prostate cancer, extended goserelin improved overall survival versus short-term ADT, with 12% relative reduction (P=.03).
In plain wordsIn men with prostate cancer, extended goserelin improved overall survival compared with short-term treatment.
Peptide
Goserelin
Outcome
IncreaseOverall survival
Study
n = 1,520
Comparator
Short-term ADT plus radiotherapy
Outcome group
Mortality · Cancer
Studied dose
3.6 mg per month · Additional 24 monthsAs given in this study (human).
Measurements
Relative reduction (overall survival)
12%
LTAD versus STAD; adjusted analysis; P=.03
Source sentences
Summary
and overall survival (12% relative reduction, P=.03).
1 context sentence(design, population, supporting numbers)
Summary · context
to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin).
Report a problemFND-2846314905
06HumanRandomized controlled trialSafety outcome
In men with prostate cancer, other-cause mortality did not differ between extended goserelin and short-term ADT (5% relative reduction, P=.48).
In plain wordsIn men with prostate cancer, deaths from other causes did not differ between extended goserelin and short-term treatment.
Peptide
Goserelin
Outcome
No significant changeOther-cause mortality
Study
n = 1,520
Comparator
Short-term ADT plus radiotherapy
Outcome group
Mortality · Cancer
Studied dose
3.6 mg per month · Additional 24 monthsAs given in this study (human).
Measurements
Relative reduction (other-cause mortality)
5%
LTAD versus STAD; adjusted analysis; P=.48
Source sentences
Summary
Other-cause mortality (non-prostate cancer) did not differ (5% relative reduction, P=.48).
1 context sentence(design, population, supporting numbers)
Summary · context
to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin).
Report a problemFND-2846314906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.